Jefferies Group LLC Halozyme Therapeutics, Inc. Transaction History

Jefferies Group LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$37.35 - $48.3 $552,667 - $714,695	-14,797 Closed	0 $0
Q1 2022 Sep 21, 2023	BUY	$31.97 - $41.06 $209,307 - $268,819	6,547 Added 79.36%	14,797 $590,000
Q1 2022 May 16, 2022	BUY	$31.97 - $41.06 $209,307 - $268,819	6,547 Added 79.36%	14,797 $590,000
Q4 2021 Sep 21, 2023	BUY	$31.82 - $40.75 $262,515 - $336,187	8,250 New	8,250 $331,000
Q4 2021 Feb 14, 2022	BUY	$31.82 - $40.75 $262,515 - $336,187	8,250 New	8,250 $332,000
Q3 2019 Nov 13, 2019	SELL	$15.2 - $17.69 $722,000 - $840,275	-47,500 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$14.75 - $17.26 $700,625 - $819,850	47,500 New	47,500 $816,000
Q3 2018 Nov 14, 2018	SELL	$16.68 - $18.41 $168,267 - $185,720	-10,088 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$16.87 - $20.3 $170,184 - $204,786	10,088 New	10,088 $170,000
Q1 2018 May 15, 2018	SELL	$17.06 - $21.2 $350,361 - $435,384	-20,537 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$16.75 - $20.8 $337,294 - $418,849	20,137 Added 5034.25%	20,537 $416,000
Q3 2017 Nov 14, 2017	BUY	$11.76 - $17.4 $4,704 - $6,959	400	400 $7,000

543

125M

294K

180K

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.62B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

Stay updated on Jefferies Group LLC with notifications on news.